eTheRNA immunotherapies NV

Activities: Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Manufacturing

etherna appoints Shelly West as Business Development Director, US

Shelly arrives from Cellpoint Biosciences and will be in charge of expanding etherna's US customer base
Ingredients

LNP formulation improves mRNA vaccine efficacy and tolerability

S-Ac7-DOG encapsulated mRNA demonstrated markedly higher transfection, lower reactogenicity, and higher accumulation in the vaccine draining lymph nodes
Research & Development

Almirall and etherna to develop mRNA-based therapies in medical dermatology

The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space
Manufacturing

eTheRNA Manufacturing announces LNP development service

The service uses the company’s proprietary lipid libraries and proprietary formulations to facilitate targeted delivery and tailored biodistribution solutions
Research & Development

eTheRNA announces mRNA research agreement with Merck

The ongoing pandemic has underlined the capability for mRNA vaccines as a therapeutic modality
Finance

eTheRNA immunotherapies opens Hong Kong office

The subsidiary will support and build on the company’s growing activities in China and broader Asia-Pacific
Research & Development

New eTheRNA led international consortium to develop COV-2 mRNA vaccineCV-19

eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations
Subscribe now